[Evaluation of dipyridamole efficacy as an agent for preventing acute respiratory viral diseases].

The epidemiological effectiveness of a low molecular interferon inducer, dipyridamole, as a means of prevention of influenza and ARD was studied in a double-blind epidemiological trial in a period of seasonal rise of ARD (Dec., 26, 1984-March 13, 1985). A statistically significant decrease of ARD incidence (1.

[Epidemiological trial of the prophylactic effectiveness of the interferon inducer dipyridamole with respect to influenza and acute respiratory diseases].

The epidemiological effectiveness of dipyridamol, an interferon-inducing agent used for the prevention of influenza and viral acute respiratory diseases, was tested in 4 epidemiological trials, 3 of them carried out as double blind trials. Observations were made in groups of adults (a research institute, a factory) and children (a kindergarten, a school), comprising 1040 subjects in the test groups and 771 subjects in the control groups. The drug was used during the whole epidemic period (January--March 1983) according to the following schedule: 1 oral administration in 8 days, in doses of 8 mg for adults, 50 mg for schoolchildren and 24 mg for children in the kindergarten.